ArticleClinical epigenetics2026
KIT-dependent acute myeloid leukemias are responsive to LSD1 inhibition.
Article in Clinical epigenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Lysine specific demethylase 1 (LSD1 or KDM1A) is a FAD-dependent histone demethylase which is overexpressed in acute myeloid leukemias (AMLs). Indeed, several selective LSD1 inhibitors (LSD1is) are currently evaluated in clinical trials. We previously demonstrated that the mammalian target of rapamycin (mTOR) signalling is inhibited in LSD1i-sensitive AMLs and is activated in LSD1i-partially responsive/tolerant AMLs following LSD1i. Herein, we sought to systematically decipher the molecular basis underlying the responsiveness of AML cells to LSD1is. Genome-wide transcriptomic profiling, RT-qPCR and immunoblot analyses revealed that stem cell factor tyrosine kinase receptor (KIT) is preferentially overexpressed in LSD1i-sensitive AMLs compared to LSD1i-partially responsive/tolerant AMLs. Pharmacological and genetic interference with LSD1 repressed KIT transcription. c-Kit acted upstream of ERK/mTOR signalling. Chromatin immunoprecipitation studies revealed that LSD1 binds in proximity to KIT TSS and modulates repressive H3K9me2 marks. Inhibiting c-Kit augmented the anti-leukemic activity of LSD1is in KIT-dependent AML cells. Consistently, KIT mRNA positively correlated with LSD1 transcript levels in primary human AML biospecimens and pharmacological LSD1i repressed KIT transcription in primary human AML samples ex vivo. Collectively, this study sheds light on the epigenetic modulation of KIT transcription by LSD1 and underscores the therapeutic potential of co-targeting LSD1/KIT in KIT-dependent AMLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.